Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Cancer Stem Cell and Tumor Environment

Overview: Cancer Stem Cell and Tumor Environment

Minami Y.

Author affiliations

Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Japan

Related Articles for ""

Oncology 2015;89(suppl 1):22-24

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Cancer Stem Cell and Tumor Environment

Published online: November 10, 2015
Issue release date: November 2015

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

It is becoming clear that cancer cells display features of normal tissue organization in the microenvironment, where cancer stem cells (CSCs) can drive tumor growth in the tumor environment. It has been proposed that the genetic and CSC models of cancer can be harmonized by considering the role of genetic diversity and tumor heterogeneity. The concept of leukemia stem cells (LSCs) also becomes critical in understanding the pathogenesis of leukemia, and alterations in the bone marrow niche are commonly observed in blood malignancies and directly contribute to the aberrant function of disease-initiating LSCs. We describe the cutting-edge progress regarding LSC research and the promising clinical strategies with LSC-targeted therapy.

© 2015 S. Karger AG, Basel


References

  1. Shackleton M, Quintana E, et al: Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-829.
  2. Kreso A, Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275-291.
  3. Ding L, Ley TJ, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-510.
  4. Lapidot T, Sirard C, et al: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.
  5. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
  6. Eppert K, Takenaka K, et al: Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-1093.
  7. Wang JCY: Bringing leukemia stem cells into the clinic. Oncology 2015;89(suppl 1):25-27.
  8. Kikushige Y, Miyamoto T: Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology 2015;89(suppl 1):28-32.
  9. Shlush LI, Zandi S, et al: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328-333.
  10. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R: Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012;4:149ra118.
  11. Yasuda T, Ueno T, et al: Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia 2014;28:426-428.
  12. Kikushige Y, Shima T, et al: Tim-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010;7:708-717.

Article / Publication Details

First-Page Preview
Abstract of Cancer Stem Cell and Tumor Environment

Published online: November 10, 2015
Issue release date: November 2015

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.